This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

Eledon Pharmaceuticals, Inc. ( ($ELDN) ) has released its Q4 earnings. Here is a breakdown of the information Eledon Pharmaceuticals, Inc.

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L antibody frexalimab, and says it plans to move the drug into a phase 3 programme next ...

The work focuses on the interaction of B cells and T cells in the body's immune system via two proteins—CD40 on B cells and CD40L on T cells—in an immune deficiency disease called X-linked ...

The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...